Sponsored content brought to you by

Ultivue logo

While current immuno-oncology research is revealing diagnostic, prognostic, and predictive cell states, and identities with implications for drug and diagnostic development as well as diagnostic testing, it is challenged in that only a minority of patients respond. Therefore, the development of robust biomarkers, enabling patient selection and design of precise combination therapies, is key for the continued success and improvement afforded by this valuable treatment. Today, spatial biology is giving researchers much-needed contextual information resolving cells and biomarkers to provide a comprehensive study of cellular composition, cellular functions, and cell–cell interactions within the tumor microenvironment (TME).

Ultivue, one of the top recognized spatial biology companies, develops unique workflows enabling multiplex immunofluorescence (mIF) insight of the TME. Its proprietary InSituPlex® technology designed for fast and comprehensive exploration of biologically relevant targets, up to 12-plex enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions coupled with their dedicated scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs.

Novel chemistry and detection means the tissue only needs mild antigen retrieval conditions during staining. This preserves tissue morphology and enables precise co-registration of multiplex images with the same H&E-stained tissue section used for pathologic diagnosis—allowing pathologists to correlate the appearance of every cell in the tissue section with its marker profile. The workflows generate a high signal-to-noise ratio, providing sensitive, robust detection of any marker used. Importantly, assay development times are reduced from months to two to three weeks, and assay run times on automated stainers are reduced from days to around five hours.

Using unique consultative spatial insight, Ultivue believes that tissue context is vital for accurate disease characterization. The company supports whole slide quantification, region or tissue compartmentalization, cellular interaction analysis, detailed cellular phenotypes and tumor landscape to provide unparalleled insight into diseased tissues.

 

Learn more ultivue.com/spatial-phenomics

Previous articleSpreading the Use of Spatial Transcriptomics
Next articleBiomarker Co-Expression Yields Insights